

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC
Petitioner,

v.

KAKEN PHARMACEUTICAL CO., LTD. and VALEANT
PHARMACEUTICALS INTERNATIONAL, INC.
Patent Owner

U.S. Patent No. 7,214,506
Issue Date: May 8, 2007
Title: Method for Treating Onychomycosis

Inter Partes Review No. 2017-01429

**Petition For *Inter Partes* Review Under
35 U.S.C. §§ 311-319 and 37 C.F.R. § 42.100 et seq.**

TABLE OF CONTENTS

EXHIBIT LISTix

I. INTRODUCTION1

II. MANDATORY NOTICES (37 C.F.R. § 42.8(a)(1))1

 A. Real Party-In-Interest Under 37 C.F.R. § 42.8(b)(1).....1

 B. Related Matters Under 37 C.F.R. § 42.8(b)(2).....1

 C. Lead And Back-Up Counsel Under 37 C.F.R. § 42.8(b)(3).....2

 D. Service Information Under 37 C.F.R. § 42.8(b)(4)2

 E. Service on Patent Owner Under 37 C.F.R. § 42.105(a) and 42.106(a)....2

III. GROUNDS FOR STANDING (37 C.F.R. §§ 42.101 and 42.104)3

IV. PAYMENT OF FEES (37 C.F.R. § 42.103).....3

V. A STATEMENT OF THE PRECISE RELIEF REQUESTED (§ 42.22(a)(1)).....3

VI. IDENTIFICATION OF CHALLENGES (§ 42.104(b))3

VII. SUMMARY OF THE '506 PATENT5

 A. Overview5

 B. The '506 Patent.....6

 C. Prosecution History10

 D. Challenged Claims of the '506 Patent.....14

VIII. EFFECTIVE FILING DATE OF THE CHALLENGED CLAIMS16

 A. The JP Priority Document Does Not Support Treating a Subject Having Onychomycosis18

 B. The JP Priority Document Does Not Disclose “topically

	administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound represented by the [chemical formula].”	19
C.	The First Disclosure of the Claimed Elements was July 11, 2000.....	21
IX.	APPLICABLE LAW AND LEVEL OF SKILL IN THE ART	21
X.	CLAIM-BY-CLAIM EXPLANATION OF GROUNDS FOR UNPATENTABILITY	23
A.	Ground 1: Claims 1 and 2 of the ’506 Patent Are Obvious Over Japanese Pat. App. Pub. No. 10- 226639 in View of Ogura.	23
	i. JP ’639 teaches “a method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound”	24
	ii. Ogura Discloses the Antifungal Activities of Azolylamine Compounds Including KP-103, <i>i.e.</i> a Compound Falling Within the Scope of the Claims	26
	iii. It Would Have Been Obvious to One of Ordinary Skill in the Art to Combine JP ’639 and Ogura.....	27
B.	Ground 2: Claims 1 and 2 of the ’506 Patent Are Obvious Over U.S. Pat. No. 5,391,367 in View of Ogura.....	32
	i. The ’367 Patent Teaches “a method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound”	33
	ii. Ogura Discloses the Antifungal Activities of Azolylamine Compounds Including KP-103.....	34
	iii. It Would Have Been Obvious to One of Ordinary Skill in the Art to Combine the Teachings of the ’367 Patent and Ogura.....	34
C.	Ground 3: Claims 1 and 2 of the ’506 Patent Are Obvious Over	

Hay in View of Ogura	37
i. Hay teaches “a method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound”	38
ii. Ogura Discloses the Antifungal Activities of Azolyamine Compounds Including KP-103.....	39
iii. It Would Have Been Obvious to One of Ordinary Skill in the Art to Combine Hay and Ogura.	39
D. Ground 4: Claims 1 and 2 of the ’506 Patent Are Obvious Over JP ’639 in View of the Kaken Abstracts	42
i. JP ’639 Teaches “a method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound”	43
ii. The Kaken Abstracts Disclose the Antifungal Activities of KP-103.	44
iii. It Would Have Been Obvious to One of Ordinary Skill in the Art to Combine the Teachings of JP ’639 and the Kaken Abstracts. .	45
E. Ground 5: Claims 1 and 2 of the ’506 Patent Are Obvious Over the ’367 Patent in View of the Kaken Abstracts.	49
i. The ’367 Patent Teaches “a method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound”	49
ii. The Kaken Abstracts Disclose the Antifungal Activities of KP-103.	50
iii. It Would Have Been Obvious to One of Ordinary Skill in the Art to Combine the Teachings of the ’367 Patent and the Kaken Abstracts.	50

F.	Ground 6: Claims 1 and 2 of the '506 Patent Are Obvious over Hay in View of the Kaken Abstracts.....	53
i.	Hay Teaches “a method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound”	53
ii.	The Kaken Abstracts Disclose the Antifungal Activities of KP-103.....	54
iii.	It Would Have Been Obvious to One of Ordinary Skill in the Art to Combine the Teachings of Hay and the Kaken Abstracts.	54
XI.	ANY EVIDENCE PATENTEE AND LICENSEE MAY OFFER RELATING TO SECONDARY CONSIDERATIONS WILL NOT BE ADEQUATE TO OVERCOME THE OBVIOUSNESS OF THE CLAIMS	57
A.	The Alleged Unexpected Results of the Invention are Insufficient to Overcome the Strong Case of Obviousness Presented Herein	59
i.	The Alleged Unexpected Results Presented During Prosecution were Known Beneficial Results.	59
ii.	The Data Presented in the '506 Specification is Flawed and Does Not Provide Evidence of an Unexpected Effect.	62
iii.	The '506 Patent Specification Demonstrates that the Claimed Compounds do not Eradicate the Infection as Claimed by Patentees.....	63
B.	Any Alleged Commercial Success of Valeant’s Jublia® Product is Insufficient to Overcome the Strong Case of Obviousness Presented Herein.....	64
XII.	CONCLUSION.....	65
	CERTIFICATION OF WORD COUNT	66
	CERTIFICATE OF SERVICE	67

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.